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Abstract
Background: The immunologic profiles of patients with human adenovirus serotype 55 (HAdV-55) infections were
characterized in subjects diagnosed with silent infections (n = 30), minor infections (n = 27), severe infections
(n = 34), and healthy controls (n = 30) during a recent outbreak among Chinese military trainees.
Methods: Blood was sampled at the disease peak and four weeks later, and samples were analyzed to measure
changes in leukocyte and platelet profiles in patients with different severities of disease. Differential lymphocyte
subsets and cytokine profiles were measured by flow cytometry and Luminex xMAPW, and serum antibodies were
analyzed by ELISA and immunofluorescence staining.
Results: Patients with severe HAdV infections had higher proportions of neutrophils and reduced levels of
lymphocytes (p < 0.005 for both). Patients with minor and severe infections had significantly lower platelet counts
(p < 0.005 for both) than those with silent infections. The silent and minor infection groups had higher levels of
dendritic cells than the severe infection group. Relative to patients with silent infections, patients with severe
infections had significantly higher levels of IL-17+CD4+ cells, decreased levels of IL-17+CD8+ cells, and higher levels
of IFN-γ, IL-4, IL-10, and IFN-α2 (p < 0.001 for all comparisons).
Conclusions: Patients with different severities of disease due to HAdV-55 infection had significantly different
immune responses. These data provide an initial step toward the identification of patients at risk for more severe
disease and the development of treatments against HAdV-55 infection.
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Background
Febrile respiratory illness (FRI) due to human adenovirus
(HAdV) infection has become a leading cause of mor-
bidity in military trainees since the cessation of HAdV
vaccine production in 1999 [1-4]. There are 65 known
serotypes of HAdV and different serotypes are associated
with pneumonia, severe respiratory failure, gastrointes-
tinal disorders, or ocular diseases. One study of an FRI
outbreak in U.S. Air Force trainees reported that almost
half of the subjects were infected with HAdV-14, some
required hospitalization, and one person died [5]. Another
study reported low morbidity and mortality of U.S. trainees
following an outbreak of HAdV-14 pneumonia, but a
higher hospitalization rate for females [4]. Given the
rapid spread and high infectivity of HAdV and the
mobility and close contact of military trainees, it is
crucial to identify biomarkers with diagnostic or prog-
nostic value.
Genome-wide computational analysis indicated that
HAdV-55, originally termed an “HAdV-B11-like” virus
[6,7], arose as a new pathogen due to recombination of
HAdV-11 and HAdV-14 [6,8]. From 2004–2006, out-
breaks occurred in Turkey, Singapore, and China (in-
correctly diagnosed as HAdV-11 at that time), with two
of these in military training bases [9,10] and one in a
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school [7]. It is unclear why HAdV-55 infection only
leads to severe pneumonia in certain patients, and there
are currently there no effective treatments.
In humans and in vivo models, the progression of AdV
infection is associated with changes in inflammatory
cells, and the inflammatory infiltrate is initially com-
posed of neutrophils and then monocytes [11,12]. As
disease progresses, lymphocytic inflammation occurs, a
response due to the innate and adaptive immune sys-
tems. The accompanying release of proinflammatory cy-
tokines, including TNF-α, IL-6, IL-1β, and IFN-γ
[11,13], is likely responsible for the resulting tissue injury
in some cases [12]. However, changes in inflammatory
cell counts may be serotype-specific, because some pa-
tients with HAdV-14 infections have significantly re-
duced counts of white blood cells, neutrophils,
lymphocytes, and platelets relative to those without in-
fection [4]. Certain AdV serotypes can suppress the
immune response [14,15]. For example, HAdV-35 sup-
presses CD4+ T cell activation through suppression of
CD46 expression [14], and HAdV-5 suppresses IFN
production through posttranslational modification [15].
To date, there has been no analysis of the immu-
nological response to HAdV-55 infection.
DNA sequencing is useful for HAdV identification,
but viral sequence alone does not determine the risk for
development of severe disease. The objective of the
present study was to examine Chinese military trainees
from one of the aforementioned HAdV outbreaks [16]
and to identify clinical and laboratory markers that have
potential diagnostic or prognostic value. This is the first
study to analyze the peripheral blood cell profiles of pa-
tients with varying severities of HAdV-55 infection at
the onset of an outbreak and four weeks after onset. The
results will provide insight into the pathogenesis of se-
vere disease due to HAdV-55 infection and help to iden-
tify markers that may ultimately be used for early
diagnosis and treatment of HAdV-55 infection.
Methods
Study population and diagnostic criteria
Two continuous outbreaks occurred at two military
camps (December 2011 to January 2012, February 2012
to March 2012), during which about 1000 soldiers were
diagnosed with a HAdV-55 infections. This study ana-
lyzed 30 patients with silent infections, 27 with minor
infections, 34 with severe infections, and 30 healthy con-
trol subjects by convenience sampling. The healthy con-
trol subjects were recruited from a different military
base in which there was no disease outbreak. All subjects
were males and 17 to 27 years-old (Table 1). Samples were
collected by throat swabs, and HAdV-55-specific DNA
was detected by real-time quantitative PCR as described
below. One blood sample was taken from subjects in the
healthy control and minor infection groups at the peak of
the outbreak (the acute phase [AP]); blood samples were
taken at the AP and four weeks later (the convalescent
phase [CP]) in the silent and severe infection groups. The
Ethics Committee of 302 Military Hospital of China ap-
proved this study and all participants provided informed
written consent.
Clinical and laboratory parameters were collected from
all patients and used for diagnosis [17]. A minor infec-
tion was defined by one of the following conditions:
upper respiratory tract infection; fever with dry throat or
sore throat; dry cough and throat congestion; lymphofol-
licular hyperplasia; spotty or flaky off-white secretions
on the tonsil surface; normal or declined white blood
cell count in the peripheral blood; decreased proportion
of lymphocytes; or increased proportion of monocytes.
A severe infection was defined by the same conditions
in addition to nodular, patchy, or large areas of consoli-
dations in lung imaging. Silent infection was defined as
the absence of clinical symptoms, but positive results for
AdV-specific IgM, as described below.
Pathogen isolation and serotype identification
Thirty throat swabs were collected from patients in the
severe infection group and were used to inoculate hu-
man adenocarcinoma A549 cells. In the first inoculation,
10 A549 cultures were inoculated with samples from 30
patients (three patients per culture dish). After the cells
were passaged twice, typical cytopathic effects (CPEs),
including cell rounding and grape-like clustering with
enhanced light refraction, occurred in five culture dishes
(samples from 15 patients). In the second inoculation,
samples from these 15 patients were individually inocu-
lated into A459 cells. Positive viral isolates were defined
by the appearance of CPEs and positive nucleic acid
tests. Cells were harvested for nucleic acid measure-
ments when CPEs were observed in 76-100% of cells. If
CPEs were absent after cells were cultured for three
Table 1 Characteristics of patients diagnosed with adenovirus type 55 infections
Healthy control (n = 30) Silent infection (n = 30) Minor infection (n = 27) Severe infection (n = 34)
Age range, years 18-25 17-21 17-24 17-27
HAdV-spec IgG+, % (n) 0 (0/30) 100 (30/30) 100 (27/27) 100 (34/34)
HAdV55-spec IgM+, % (n) 0 (0/30) 90.0 (18/20) 86.7 (13/15) 100 (34/34)
HAdV-55 DNA+ % (n) 0 (0/30) 3.3 (1/30) 30 (9/30) 41.2 (14/34)
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generations, and no viral nucleic acid was detected, the
isolate was considered negative. A total of eight viral
clones were ultimately isolated.
For inoculation, samples were placed in tubes con-
taining 2 mL of HBSS (Sigma-Aldrich, St Louis, MO,
USA), and these tubes were oscillated for 30 sec and
then centrifuged at 1500 rpm for 10 min. The super-
natant was collected, 1000 U/mL each of penicillin and
streptomycin (Life technologies, Carlsbad, CA, USA)
were added, the sample was incubated at 4°C for 2 h,
and the solution was inoculated onto a monolayer of
A549 cells. The cells were cultured in DMEM that
contained 10% fetal bovine serum and 100 U/mL each
of penicillin, streptomycin, and kanamycin (all from
Life Technologies) at 32°C with 5% CO2, and examined
by microscopy daily.
Nucleic acids were extracted using the QIAmpMiniElute
Virus Span kit (Qiagen, Hilden, Germany), following manu-
facturer’s instructions. Three sets of PCR primers were
used to confirm that the isolated virus was an adeno-
virus: an AdV general primer pair [18], a primer pair for
the AdV B group Hexon, and a primer pair for the AdV
B group Fiber [19] (Table 2). Purified viral genomic
DNA was used as the template for the PCR reaction that
included the following reagents in 25 μL: 10 × buffer
(2.5 μL), 10 mM dNTP mix (2 μL), 50 mM upstream
and downstream primers (0.5 μL each), DNA polymer-
ase (0.3 μL), and the DNA template (2 μL). The thermo-
cycling regimen was: one cycle at 94°C for 3 min,
35 cycles at 94°C for 30 sec, 55°C for 45 sec, 72°C for
45 sec, and a final elongation step at 72°C for 10 min.
The amplification products were separated by 2% agarose
gel electrophoresis. The sequence of HAdV-55 is 98.86%
identical to HAdV-14 [6,8], so HAdV-55 identification
was confirmed by sequencing of PCR products (Life
Technologies) to identify the virus serotype and the se-
quence was submitted to the NCBI database for BLAST
analysis and to the gene bank of the Chinese PLA
Center for Disease Control and Prevention. Table 1
shows the proportion of samples that were positive for
HAdV-55 nucleic acids.
Detection of serum antibodies
HAdV55 is a new strain of virus, so no HAdV-55-
specific IgG ELISA kit is available. Thus, we used a
commercially available HAdV-specific IgG ELISA kit
(RE56571 Adenovirus IgG; IBL, Hamburg, Germany) to
measure the increase of HAdV-specific IgG during the
acute and convalescent phases An AdV-specific IgG
level greater than 12 U/mL is defined as positive accord-
ing to the manufacturer’s instruction. Subsequently, all
cases with 4-fold increase in AdV-specific IgG were fur-
ther confirmed by HAdV-55-spec IgG immunofluores-
cence as the methods described below. Another
adenovirus ELISA kit (RE56581 Adenovirus IgM; IBL) is
specific for adenovirus type 5 Hexon antigen, but not
for HAdV-55, so detection of HAdV-55-specific IgM
(HAdV55-IgM) was performed by an immunofluores-
cence (IF) assay. A549 cells were inoculated with the
isolated virus strains to prepare viral antigen slides for
detection of serum IgM and IgG by IF assay. Specific-
ally, A549 cells with positive viral isolation results were
freeze-thawed, and a 1 × 10−3 dilution was used to in-
oculate the A549 cells. When CPEs occurred in ~50% of
cells, they were harvested, washed with PBS (pH 7.4)
three times, and fixed with cold acetone overnight. After
drying, the antigen slides were divided into small pieces
(0.3 × 0.3 cm2) and stored at -20°C until use. Uninfected
A549 cell slides were prepared as controls.
For IF analysis, antigen slides were fixed on a glass
slide with the cell side facing up, washed three times
with PBS, blocked with bovine serum albumin for
20 min, and then incubated with 50 μL of diluted patient
serum (1:20 for IgM and 1:50 ~ 1: 800 for IgG in PBS).
Slides incubated with 50 μL PBS served as a negative
control. Samples were incubated in a moist chamber at
4°C overnight, washed with three times with PBS, and
incubated with FITC-conjugated rabbit anti-human IgM
(ZF-0307, 1:150 dilution; OriGene, Rockville, MD, USA)
or anti-human IgG (ZF-0308, 1:150 dilution; OriGene).
After incubation in a moist chamber at 37°C for 40 min
and a rinse with PBS, nuclei were stained with Evans
blue, and slides were mounted with glycerol and ob-
served by fluorescence microscopy (Nikon-80i, Japan) at
400× magnification. Table 1 shows the proportion of pa-
tients who were positive for adenovirus specific HAdV-
IgG and HAdV55-IgM. The HAdV-55-IgM fluorescence
intensity was scored from 0 (no positive cells) to 4 (high-
est fluorescence). Each slide was scored by two experi-
enced pathologists, and average scores were recorded.
Analysis of blood cells and lymphocyte subsets
Hematologic tests were performed using Sysmex XE 2100
(Kobe, Japan). Flow cytometry used fluorophore-
conjugated antibodies (BD Biosciences, San Jose, CA,
USA) and FACSCalibur and CELLQuest software (BD
Table 2 PCR primers used in RT-PCR analysis
Target Direction Sequence (5′→3′) Product
size (bp)
Universal Forward TTCCCCATGGCICAYAACAC 482
Reverse CCCTGGTAKCCRATRTTGTA
Hexon Forward TTGACTTGCAGGACAGAAA 590
Reverse CTTGTATGTGGAAAGGCAC
Fiber Forward TACCCCTATGAAGATGAAAGCA 1064
Reverse GGAGGCAAAATAACTACTCG
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Biosciences) to detect lymphocyte subsets, dendritic cells
(DCs), IL-17+ T cells, and activated T cells. Peripheral
blood lymphocyte (PBL) subsets were determined using a
MultiTEST IMK kit (BD Biosciences) following the manu-
facturer’s instructions. CD3+ T lymphocytes were CD3
+CD45+; CD4+ T lymphocytes were CD3+CD4+CD45+;
CD8+ T lymphocytes were CD3+CD8+CD45+; B lympho-
cytes were CD3−CD19+ CD45+; and natural killer (NK)
cells were CD3−CD16+CD56+CD45+. DCs were identified
using a combination of CD123-PE, HLA-DR-Percp, Lin-
1-FITC, and CD11c-APC antibodies. Plasmacytoid DCs
(pDCs) were Lin-1−HLA-DR+CD123+ and myeloid DCs
(mDCs) were Lin-1−HLA-DR+CD11c+. A combination of
antibodies specific for CD3-APC, CD8-Percp, IFN-γ-
FITC, and IL-17-PE were used to identify Th17 cells. Acti-
vated T cells were identified using a combination of
CD3-APC, CD8-Percp, CD38-FITC, and CD56-PE anti-
bodies. Data were analyzed with FlowJo 7.0 software.
Analysis of cytokine levels
Cytokine levels were assessed using the FLEXMAP 3D sys-
tem (Luminex, Austin, TX, USA) and a human cytokine kit
(Milliplex, Catalog no. MPXHCYTO-60 K-16, Millipore,
Billerica, MA, USA) following the manufacturer’s instruc-
tions. The selected cytokines were Fractalkine, IFN-α2,
IFN-γ, IL-1β, IL-2, IL- 4, IL-5, IL-6, IL-8, IL-10, IL-15, IL-
17, MCP-3., MIP1-A, MIP1-B, TNF-α, and IL-12.
Statistical analysis
Categorical data are presented as counts and percentages
and continuous data as means and standard deviations
(SDs). Comparisons among groups were performed using
one-way ANOVA with the Bonferroni post hoc correction.
Due to the small sample size, Figures 1, 2 and 3, and
Additional file 1: Tables S2 and Additional file 1: S3 show
the baseline lymphocyte and CD38 levels and cytokine
levels at two phases with medians and range. Comparisons
among groups were performed by the non-parametric
Kruskal-Wallis test and when the results were statistically
significant, multiple tests for pairwise comparisons with the
Bonferroni correction were performed using the non-
parametric Mann–Whitney test. The significance of within-
group differences of the two disease phases (AP vs. CP)
were assessed using the Wilcoxon signed-rank test. A two-
tailed p-value less than 0.05 was considered statistically sig-
nificant. Statistical analyses were performed with SPSS 15.0
(Chicago, IL, USA).
Results
Diagnosis of HAdV-55 infection
We analyzed patients for the presence of HAdV-55 in-
fection based on antibody titer and the presence of viral
DNA (Table 1). All samples from the control group were
negative in all 3 tests. HAdV specific IgG was present in
100% of the samples of the three infection groups.
HAdV55-specific IgM was present in 90% of patients
with silent infections, 86.7% of patients with minor in-
fections, and 100% of patients with severe infections.
HAdV-55 DNA was present in 3.3% of patients with si-
lent infections, 30% of patients with minor infections,
and 41.2% of patients with severe infections.
Effect of HAdV-55 infection on blood cell counts
The four groups had similar WBC counts during the AP,
but there were significant differences in the proportions
of neutrophils, lymphocytes, monocytes, and platelets
during this phase (Table 3). In particular, the severe in-
fection group had a greater proportion of neutrophils
than the silent infection and minor infection groups
(p < 0.005 for both), and a smaller proportion of lympho-
cytes than the silent infection group (p < 0.005). The
minor and severe infection groups had significantly
higher proportions of monocytes than the control and
silent infection groups (p < 0.005 for all). The silent in-
fection group had significantly higher PLT counts than
the healthy group, the minor infection group, and the
severe infection group (p < 0.005 for all).
The blood cell counts were very different during the
CP (Table 3). Relative to the AP (baseline), the severe in-
fection group had significantly lower proportions of neu-
trophils (0.61 vs. 0.50; p < 0.0001) and monocytes (0.11
vs. 0.09 and; p < 0.05), and a higher proportion of lym-
phocytes (0.27 vs. 0.39, p < 0.0001). The severe infection
group had greater PLT counts at the CP relative to base-
line (253.0 vs. 181.47 × 109/L; p < 0.0001), but the silent
infection group had significantly lower PLT counts rela-
tive to baseline (224.37 vs. 260.40 109/L, p < 0.0001).
Effect of infection severity on IgM IF score
We also compared the HAdV55-IgM IF scores of the si-
lent, minor, and severe infection groups (Figure 4). As
expected, all patients in the control group had IF scores
of 0 (data not shown). Somewhat unexpectedly, patients
in silent and severe infection groups had significantly
higher IF scores than patients in the minor infection
group (p < 0.003 and p < 0.001, respectively). In
addition, 55.0% of the silent infection group and 38.2%
of the severe infection groups had IF scores of 3 or
more, but all patients in the minor infection group had
IF scores less than 3. Additional file 1: Table S1 summa-
rizes the changes in Adv-specific IgG titer from the AP
to the CP in the patients of silent infection and severe
infection groups.
Lymphocyte subsets in patients and controls
We also analyzed the lymphocyte subsets in all four
groups at the AP (Figure 1). Subjects with silent infec-
tions had significantly higher numbers of CD3+ cells
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(median: 1523.0/mm3), CD4+ cells (median: 687.0/mm3),
and CD8+ cells (median: 677.5/mm3). There were no sig-
nificant differences in these three lymphocyte subsets
among the other 3 groups. The silent infection group
had significantly higher NK cell counts (median: 427.0/mm3)
than the minor and severe infection groups. The
percentage of IFN-γ+CD8+ cells among all CD8+ T cells
was significantly higher in the severe infection group than
in the minor infection group (median: 15.7 vs. 11.5, p=
0.006). Additional file 1: Table S2 summarizes the changes
in the lymphocyte subsets of each group from the AP to
the CP.
Figure 1 Lymphocyte subsets of the different groups of patients in the AP phase, determined using flow cytometry. Here and below,
solid horizontal lines indicate medians. *Significantly different from the healthy control group. †Significantly different from the silent infection
group. ‡Significantly different from the minor infection group.
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We also determined the percentage of activated T cells
(CD38+ cells) among peripheral blood lymphocytes
(PBL) at baseline (Figure 2). There were more CD38+
cells in the minor and severe infection groups than in
the healthy and silent infection groups among CD4+
cells, but this difference was not statistically significant.
There were significantly more CD38+ cells in the minor
and severe infection groups than in the healthy and si-
lent infection groups among CD8+ cells (CD4+: 5.13 and
9.14 vs. 1.67 and 2.49, respectively, p < 0.001; CD8+: 4.28
and 12.90 vs. 1.03 and 0.75, respectively, p < 0.001;
Figure 2).
At the CP, the silent and severe infection groups had
no significant changes in the counts of CD3+, CD4+, and
CD8+ cells relative to baseline; however, these counts were
greater than the control group at baseline (p ≤ 0.001 for
all comparisons; Additional file 1: Table S2). The silent in-
fection group had significantly lower lymphocyte and NK
cell counts in the CP than at baseline; however, the severe
infection group had significant increases in these counts
relative to baseline (p < 0.0021). Although the silent infec-
tion group had decreased lymphocyte counts at the CP,
they remained higher than the healthy control and minor
infection groups (means of 2162.40/mm3, 1717.93/mm3,
and 1692.26/mm3 respectively). The silent and severe
infection groups had significantly higher B cell counts
at the CP than at baseline (p < 0.05; Additional file 1:
Table S2).
Effects of HAdV-55 infection severity on DC and Th17
cells
Analysis of PBLs indicated that the silent and minor in-
fection groups had significantly higher mDC and pDC
levels than the control and severe infection groups in
the AP (p < 0.05 for all comparisons; Table 4). The se-
vere infection group had significantly higher mDC/
PBMC and pDC/PBMC ratios in the CP relative to base-
line (0.70 vs. 0.53 and 0.38 vs. 0.22, respectively).
In the AP, patients with severe infections had the high-
est median level of IL-17+CD4+ cells (p < 0.05 for all
comparisons; Figure 1 and Table 4). In contrast, the si-
lent and minor infection groups had higher levels of
IL-17+CD8+ cells than the control group at baseline,
and the severe infection group had lower levels of
these cells than the silent infection group. Finally, the
silent and severe infection groups had higher levels of
IL-17+CD4+ and IL-17+CD8+ cells at the CP relative to
their levels at baseline and relative to those in the
control and minor infection groups (Table 4).
Effect of HAdV-55 infection on cytokine expression
Figure 3 shows the levels of 6 cytokines in the different
groups during the AP and CP. In the AP, the minor and
severe infection groups had significantly higher levels of
IFN-γ, IL-10, and IFN-α2 than the healthy control and
silent infection groups. The severe infection group had a
higher level of IL-4 than all other groups, and the silent
and minor infection groups had a higher level of IL-4
relative to the control group. The severe infection group
had a significantly higher level of IL-15 than the control
group. The silent and severe infection groups had higher
levels of MCP-3 relative to the control group, but there
was no significant difference between the control and
minor infection groups.
The severe infection group had significantly lower
levels of IFN-γ, IL-4, IL-10, IL-15, and IFN-α2 during
the CP than during the AP. The three groups (control,
silent infection, severe infection) had no significant dif-
ferences in the levels of any of the tested cytokines
during the CP. Additional file 1: Table S3 summarizes
the data for all of the cytokines analyzed during the
AP and CP.
Discussion
This purpose of this cross-sectional study was to eluci-
date the clinical characteristics of patients with HAdV-
Figure 2 Percentage of CD38+ cells of the different groups of patients in the AP phase. *Significantly different from the healthy control
group. †Significantly different from the silent infection group. ‡Significantly different from the minor infection group.
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55 infections as a first step toward the identification of
biomarkers that can be used to predict disease severity.
Our results indicated that patients with silent infections,
minor infections, severe infections, and healthy controls
had significant differences in the proportions of neutro-
phils, lymphocytes, monocytes, and PLT counts during
the AP of HAdV-55 infection. Patients with more severe
infections had more neutrophils, fewer lymphocytes, and
significantly lower PLT counts. In addition, the silent
and minor infection groups had significantly higher
mDC and pDC levels. Patients with severe disease had
increased levels of IL-17+CD4+ cells, decreased levels of
IL-17+CD8+ cells, and higher levels of IFN-γ, IL-4, and
IL-10. In addition to HAdV-55 outbreaks, there have
been other reports of outbreaks of HAdV types in which
pneumonia was observed in immunocompetent adults
[20-22]. In particular, Cao et al. [22] compared the epi-
demiological and clinical characteristics of Chinese pa-
tients infected with different HAdV types and found that
patients with HAdV-55 infections were older and had
Figure 3 Cytokine levels in the AP and CP phases of the different groups of patients. (A) IFN-γ, (B) IL-4, (C) IL-15, (D) IL-10, (E) MCP-3, and
(F) IFN-α2. The dotted line indicates the lower limit of detection. aSignificantly different from the control group. bSignificantly different from the
silent infection group at the AP phase. *Significantly different from the baseline level within group (CP phase vs. AP phase).
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more severe pneumonia than patients infected by other
HAdV types. However, these other studies focused on
the epidemiology and clinical features of the infection
rather than peripheral blood cell profiles of infected pa-
tients. The present study is the first to analyze the per-
ipheral blood cell profiles of patients with varying
severities of HAdV-55 infections during the AP and CP
and to identify potential biomarkers that may ultimately
be used to predict disease severity.
HAdV infection leads to neutrophil accumulation and
then monocyte infiltration of the lungs [11,12]. In the
present study, we observed increased serum levels of
neutrophils and monocytes in the severe infection group
at the AP. In the CP, the proportions of neutrophils and
monocytes significantly decreased to the levels of the
healthy control group. Generally, there is a transient in-
crease of neutrophils following an infection. This is con-
sistent with our observation of elevated levels of
neutrophils and monocytes during the AP, and decreased
levels during the CP. These changes are similar to those
reported for infection by Type A H1N1 [23]. Further
studies of target organs, such as the lungs, will be
Figure 4 HAdV55-IgM IF scores in subjects with silent, minor, and severe infections.











WBC, 109/L 5.18 ± 1.21 AP 6.03 ± 1.13 5.49 ± 1.58 6.21 ± 2.96 0.1333
CP 6.17 ± 1.32b ND 5.78 ± 1.40 0.0164a
Neutrophil, fraction 0.57 ± 0.08 AP 0.51 ± 0.09 0.51 ± 0.14 0.61 ± 0.15c,d 0.0020a
CP 0.52 ± 0.08 ND 0.50 ± 0.09b,e 0.0026a
Lymphocyte, fraction 0.34 ± 0.07 AP 0.38 ± 0.08 0.34 ± 0.15 0.27 ± 0.13c 0.0009a
CP 0.36 ± 0.08 ND 0.39 ± 0.08e 0.0609
Monocyte, fraction 0.07 ± 0.02 AP 0.09 ± 0.02 0.13 ± 0.03b,c 0.11 ± 0.04b,c <0.0001a
CP 0.09 ± 0.02 ND 0.09 ± 0.02e 0.0001a
PLT, 109/L 207.13 ± 36.88 AP 260.40 ± 54.22b 213.81 ± 47.54c 181.47 ± 48.33c <0.0001a
CP 224.37 ± 39.78e ND 253.00 ± 51.70b,c,e 0.0004a
AP, acute phase; CP, convalescent phase; ND, not determined; WBC, white blood cells; PLT, platelet.
asignificant differences in the four groups by one-way ANOVA.
bsignificant difference from the healthy control group.
csignificant difference from the silent infection group.
dsignificant difference from the minor infection group.
esignificant difference from the AP phase within a group.
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needed to determine if increased levels of these cells cor-
respond with pulmonary infiltration.
In the AP, patients with silent infections had higher
PLT counts than healthy controls, but the minor and se-
vere infection groups had PLT counts similar to the
healthy controls. However, in the CP, the severe infection
group had a significantly elevated PLT count relative to
the healthy controls. PLTs can produce thrombocidins,
antimicrobial peptides that are produced in response to
infectious agents [24]. Thus, it is possible that the ele-
vated PLT count in the silent infection group during the
early stage of the infection may have contributed to their
absence of symptoms.
DCs are critical for the activation of the immune re-
sponse to AdV infection [25,26]. AdV infection causes
pDCs to produce large amounts of type I interferon,
which has pleiotropic anti-viral effects in the early phase
of infection. The mDCs present the virus antigen to
adaptive cells, which secrete interleukins (mainly IL-12)
that activate other immune cells. We observed increased
levels of mDCs and pDCs in the silent and minor infec-
tion groups during the AP, but not in patients with se-
vere infections. However, in the CP, the levels of mDCs
and pDCs increased in the severe infection group to
levels comparable to those of the silent infection group
at that time.
Patients with severe HAdV-55 infections had increased
levels of Th17 cells. A previous study of severe respira-
tory syncytial virus (RSV) infection indicated that
neutralization of IL-17 significantly reduced inflamma-
tion and viral counts, possibly due to increased CD8
cytotoxic T cell activation [27]. Another study reported
that reductions in Th17 cells were associated with T cell
activation in patients with H1N1 influenza A infection
[28]. Studies of the role of IL-17 in the pathogenesis of
this virus may be useful for the design of treatments.
Patients with different severities of HAdV-55 infection
expressed different proinflammatory cytokines. For ex-
ample, the severe infection group had higher levels of
IL-10 than the silent infection group during the AP.
Thus, it is possible that more regulatory T cells were in-
duced or activated in patients with severe infections,
possibly due to an inhibition of the anti-viral response.
Previous studies in children with HAdV infections, in-
cluding HAdV-3 and HAdV-7 [29-31], reported no dif-
ferences in the levels of IL-10 in controls and infected
patients, suggesting that this response may be unique to
HAdV-55 infection. Interestingly, we only observed in-
creased IFN-γ levels in patients with severe infections
during the AP. This is consistent with other in vivo stud-
ies of AdV infections [11,32] and with the transient in-
crease of IFN-γ in H1N1 influenza infections [33].
Pathogens are routinely collected from oropharyngeal
swabs of patients with respiratory tract infections. Clinical
diagnosis is based on symptoms, signs, and epidemiological
data and laboratory diagnosis is based on etiological and
immunological data. Not all cases are suitable for etiological
examination because sample time is crucial. If a pathogen
is detected and a clinical diagnosis is indicated, there can be
a definitive diagnosis. Similarly, specific immunological data
can generally be used to make a definitive diagnosis. How-
ever, for certain diseases in which there is no known
Table 4 Analysis of lymphocyte subsets in the different groups at the acute phase (AP) and receding pandemic (CP)
phases









mDC/PBMC, % 0.53 ± 0.13 AP 1.09 ± 0.34b 0.81 ± 0.48b,c 0.53 ± 0.24c,d <0.0001a
CP 0.89 ± 0.43b,e ND 0.70 ± 0.30e 0.0014a
pDC/PBMC, % 0.24 ± 0.11 AP 0.42 ± 0.21b 0.39 ± 0.23b 0.22 ± 0.14c,d <0.0001a
CP 0.37 ± 0.22b ND 0.38 ± 0.12b,e 0.0048a
IFN-γ+CD4/CD3, % 23.09 ± 6.03 AP 17.41 ± 7.75b 16.13 ± 5.60b,d 23.94 ± 6.72c,d <0.0001a
CP 23.38 ± 6.81e ND 24.50 ± 8.73 0.0001a
IFN-γ + CD8/CD3, % 14.30 ± 5.65 AP 15.88 ± 8.17 12.53 ± 6.33 18.30 ± 8.23 0.0251
CP 23.30 ± 8.94b,e ND 18.40 ± 8.66d 0.0003a
IL-17+CD4/CD3, % 2.06 ± 0.94 AP 1.74 ± 0.96 1.93 ± 0.89d 2.84 ± 1.19b,c,d 0.0004a
CP 3.37 ± 1.47b,e ND 3.04 ± 1.36b 0.0002a
IL-17+CD8/CD3, % 0.22 ± 0.17 AP 0.54 ± 0.33b 0.40 ± 0.22b,d 0.25 ± 0.18c <0.0001a
CP 0.81 ± 0.34b ND 0.74 ± 0.69b <0.0001a
DC, dendritic cell; AP, acute phase; PBMC, peripheral blood mononuclear cell; CP, convalescent phase; ND, not determined.
asignificant differences in the four groups by one-way ANOVA.
bsignificant difference from the healthy control group.
csignificant difference from the silent infection group.
dsignificant difference from the minor infection group.
esignificant difference from the AP within a group.
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production of specific antibodies or available diagnostic
test, it is necessary to combine clinical signs with laboratory
data for diagnosis. A positive pathogen test result alone
cannot be used to determine disease severity. The low
number of pathogens in our silent infection group demon-
strated that viral copy number was low or that there was
rapid virus elimination due to a strong immune response.
In the present study, we only observed HAdV-55 DNA in
41% of patients with severe infections and 30% of patients
with minor infections, so this parameter cannot be used to
indicate infection severity or disease progression. Analysis
of IgG and IgM-specific AdV antibodies was more reliable
in the identification of patients with AdV infections. Fur-
thermore, analysis of the HAdV55-specific IgM IF score in-
dicated that patients with severe and silent HAdV-55
infections had significantly higher scores than those with
minor infections. It is possible that patients with silent in-
fections had strong immune responses (high IF scores) and
this prevented clinical symptoms; patients with minor in-
fections had weak immune responses (low IF scores) and
some clinical symptoms; and patients with severe infections
had strong immune responses, but a higher viral load that
made their disease more severe. This explanation is consist-
ent with our observation that more patients with severe dis-
ease had evidence of HAdV-55 DNA (Table 1) and became
more immunocompromised (Additional file 1: Table S3)
than the other groups. Further studies are needed to con-
firm this explanation.
This study is limited in that only peripheral blood was
sampled for analysis, and there were no samples from in-
fected organs, such as the lungs. Thus, it is unclear if the
altered cell counts that we observed were due to changes
in the total number of cells or due to migration of cells to
target organ(s). Furthermore, if alterations in PBLs are
to be used to predict disease progression, it is necessary to
have more detailed information about whether the PBL
parameters changed before, during, or after manifestations
of severe disease. Another limitation is that although there
were several HAdV-55 outbreaks during this time period
in China, we only examined one outbreak. Thus, these re-
sults need to be confirmed by studies of other outbreaks
of HAdV-55. Finally, our study was limited to infection by
one HAdV-55 serotype, so the results should not be gen-
eralized to other serotypes.
Conclusion
This is the first study to analyze the peripheral blood cell
profiles of patients with HAdV-55 infections. Patients with
silent, minor, and severe infections had significant diffe-
rences in IgM IF scores, blood cell counts, lymphocyte sub-
sets, and cytokine levels. These results provide a foundation
for use of the immunological profiles of patients with
HAdV-55 infections for estimation of prognosis.
Additional file
Additional file 1: Table S1. Changes of IgG titers from the acute
phase to the convalescent phase in the patients of silent infection and
severe infection groups. Table S2. Lymphocyte subsets of the different
groups of patients in the AP and CP. Table S3. Cytokine levels of the
different groups of patients in the AP and CP.
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